On Dec. 2, 2022, in a multi-center collaboration led by Scripps Research, scientists announced they have achieved promising results in the first-in-human clinical trial of a novel HIV vaccine.

The trial results, published in Science, showed that the vaccine had a favorable safety profile and induced the targeted response in 97% of people who were vaccinated.